Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Causality | 6 | 2024 | 1248 | 0.920 |
Why?
|
| Models, Statistical | 4 | 2023 | 5089 | 0.710 |
Why?
|
| Biology | 1 | 2022 | 293 | 0.700 |
Why?
|
| Vaccines | 2 | 2024 | 841 | 0.600 |
Why?
|
| AIDS Vaccines | 2 | 2021 | 898 | 0.570 |
Why?
|
| Growth Disorders | 3 | 2023 | 633 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 7 | 2024 | 2010 | 0.420 |
Why?
|
| Cachexia | 2 | 2023 | 200 | 0.380 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 3211 | 0.360 |
Why?
|
| Survival Analysis | 1 | 2023 | 10070 | 0.350 |
Why?
|
| Research Design | 3 | 2024 | 6209 | 0.350 |
Why?
|
| Developing Countries | 3 | 2023 | 2911 | 0.270 |
Why?
|
| Malaria Vaccines | 1 | 2024 | 165 | 0.200 |
Why?
|
| Squalene | 1 | 2021 | 36 | 0.180 |
Why?
|
| Polysorbates | 1 | 2021 | 46 | 0.180 |
Why?
|
| Malnutrition | 2 | 2023 | 629 | 0.170 |
Why?
|
| Sample Size | 1 | 2022 | 845 | 0.160 |
Why?
|
| Probability | 2 | 2022 | 2475 | 0.150 |
Why?
|
| HIV Infections | 2 | 2021 | 17533 | 0.140 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 14751 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2023 | 6322 | 0.130 |
Why?
|
| Malaria, Falciparum | 1 | 2024 | 1075 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 995 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2023 | 6255 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 689 | 0.110 |
Why?
|
| Air Pollution, Indoor | 1 | 2022 | 931 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 2686 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2023 | 3564 | 0.090 |
Why?
|
| Humans | 20 | 2024 | 765968 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2023 | 12768 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 878 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3655 | 0.070 |
Why?
|
| Immunoglobulin G | 3 | 2023 | 4528 | 0.070 |
Why?
|
| Software | 1 | 2020 | 4462 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 2178 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8041 | 0.060 |
Why?
|
| Rain | 1 | 2023 | 61 | 0.050 |
Why?
|
| HIV-1 | 1 | 2021 | 6944 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9525 | 0.050 |
Why?
|
| Ghana | 1 | 2024 | 333 | 0.050 |
Why?
|
| Mothers | 2 | 2023 | 2210 | 0.050 |
Why?
|
| Canarypox virus | 1 | 2021 | 10 | 0.050 |
Why?
|
| Infant | 4 | 2024 | 36386 | 0.050 |
Why?
|
| Kenya | 1 | 2024 | 758 | 0.050 |
Why?
|
| Nepal | 1 | 2022 | 301 | 0.040 |
Why?
|
| Selection Bias | 1 | 2022 | 361 | 0.040 |
Why?
|
| Sodium Selenite | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cooking | 1 | 2022 | 327 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 552 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2023 | 26346 | 0.040 |
Why?
|
| Anthropometry | 1 | 2023 | 1338 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2022 | 993 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 373 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 319 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 1524 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 649 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 967 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 951 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2023 | 42500 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13648 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 590 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 10383 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 657 | 0.030 |
Why?
|
| South Africa | 1 | 2021 | 1867 | 0.030 |
Why?
|
| Diarrhea | 1 | 2022 | 1316 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2652 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 1519 | 0.030 |
Why?
|
| Malaria | 1 | 2024 | 1246 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2024 | 1738 | 0.030 |
Why?
|
| Vaccination | 1 | 2024 | 3426 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 26318 | 0.020 |
Why?
|
| Female | 7 | 2024 | 396112 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2021 | 3404 | 0.020 |
Why?
|
| Adult | 5 | 2024 | 223044 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2023 | 3425 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2019 | 4260 | 0.020 |
Why?
|
| Genotype | 1 | 2024 | 13024 | 0.020 |
Why?
|
| Sex Factors | 1 | 2023 | 10603 | 0.020 |
Why?
|
| Cell Survival | 1 | 2019 | 5747 | 0.020 |
Why?
|
| Male | 5 | 2024 | 363698 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10729 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12437 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 14652 | 0.020 |
Why?
|
| Cognition | 1 | 2023 | 7049 | 0.020 |
Why?
|
| Incidence | 1 | 2023 | 21480 | 0.010 |
Why?
|
| Young Adult | 2 | 2021 | 59889 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 88835 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 30260 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 41649 | 0.010 |
Why?
|
| Aged | 2 | 2024 | 171117 | 0.010 |
Why?
|
| Middle Aged | 2 | 2024 | 223009 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40065 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54802 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23601 | 0.010 |
Why?
|
| United States | 1 | 2021 | 72903 | 0.010 |
Why?
|
Concepts
(95)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_